JS InnoPharm

About JS InnoPharm

JS InnoPharm is a clinical-stage biopharmaceutical company established in 2010 with headquarters in Shanghai and additional offices in Suzhou, China. The firm is dedicated to the discovery and development of new small molecule chemical entities for oncology, with a focus on precision medicine that utilizes advanced knowledge of mutations and biomarkers. The company's business model involves in-house research and development, supplemented by global partnerships and licensing agreements to build its therapeutic pipeline. Dr. Jintao Zhang serves as the CEO of the company.

JS InnoPharm offers drug discovery outsourcing services, which include molecular design, synthesis, and various biological activity evaluations. A key area of focus for the company is the MAPK signaling pathway, which is critical in cancer cell growth. One of its lead drug candidates is JSI-1187, a selective, orally administered small molecule inhibitor of ERK1 and ERK2 enzymes. This candidate has shown high potency against tumors with MAPK pathway mutations in preclinical studies and has advanced to Phase 1 clinical trials in the United States. The trials, managed by its U.S. clinical development partner Strategia Pharmaceuticals, are evaluating JSI-1187 both as a monotherapy and in combination with other inhibitors like dabrafenib for patients with advanced solid tumors.

The company has established significant strategic partnerships to accelerate global drug development. In 2018, it formed an alliance with U.S.-based Strategia Holdings, LLC, and its associated biopharmaceutical companies to combine expertise and resources from both the U.S. and China. This collaboration aims to enhance development efficiencies and success rates. Through these partnerships, JS InnoPharm has engaged in sub-licensing agreements, such as the one with Spirita Oncology for the global clinical development of E6201, a MEK1 inhibitor. The company is privately held and has received venture capital funding through multiple rounds, including Series A, A1, and B, with investors such as Baidu Ventures and Hangzhou Tigermed Consulting Company.